New updates have been reported about Sword Health.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Sword Health is expanding beyond digital musculoskeletal care with the launch of Pulse, an AI-driven cardiometabolic solution targeting hypertension, pre-diabetes, type 2 diabetes, weight management, high cholesterol, and GLP-1 support, positioning the company in one of the largest and fastest-growing U.S. health cost categories. Built on Sword’s existing AI care infrastructure, Pulse combines an always-on AI agent, Phoenix, connected health devices, and evidence-based lifestyle interventions to deliver continuous, personalized support aimed at reducing long-term cardiometabolic risk and associated medical spend.
For employers and health plans, Sword is introducing outcomes-based lump-sum pricing for Pulse, with half of the payment tied to member activation and the remaining half contingent on demonstrable health improvement, directly aligning the company’s revenue with clinical and financial results. The product also targets the rapidly expanding GLP-1 user base by offering tailored strength training, nutrition guidance focused on protein intake, and body composition monitoring to mitigate muscle loss and bone health risks, reinforcing Sword’s value proposition as GLP-1 usage scales.
Pulse uses a three-way communication model that links the member, a matched health specialist, and Phoenix, allowing the AI to manage daily engagement, interpret data from devices such as blood pressure cuffs, scales, and wearables, and escalate complex issues to human clinicians as needed, thereby addressing access gaps in primary and preventive care. This model is designed to convert episodic, reactive care into continuous, proactive management while tackling structural constraints such as long wait times for primary care and low national spending on prevention.
The cardiometabolic launch leverages Sword Health’s broader platform scale, which has delivered more than 11 million AI care sessions to over 800,000 members and generated more than $1 billion in estimated avoided healthcare costs for over 1,000 enterprise clients, including 20% of the Fortune 500, major health plans, and government entities. Backed by more than $500 million in capital and supported by 58 clinical studies and 50 patents, Sword is betting that tying Pulse’s economics to measurable outcomes will differentiate it from traditional per-member-per-month or utilization-based digital health vendors.
Management frames cardiometabolic disease as the next major growth vector for the business, citing projections that more than 184 million Americans will have some form of cardiovascular disease by 2050 and that annual costs already exceed $400 billion, creating a large addressable market for value-based, AI-enabled prevention and disease management. Pulse will initially be offered to self-insured employers and health plans as a wellness benefit later in 2026, with Sword aiming to replicate in cardiometabolic care the same cost savings and clinical performance that underpinned its rapid growth in musculoskeletal, women’s health, and mental health.